Skip to main content
TipRanks
Go Ultimate75% OFF

Bicara Therapeutics Inc. (BCAX) Stock Statistics & Valuation Metrics

93 Followers

Total Valuation

Bicara Therapeutics Inc. has a market cap or net worth of $647.28M. The enterprise value is $831.00M.

Market Cap
$647.28M
Enterprise Value
$831.00M

Share Statistics

Bicara Therapeutics Inc. has 66,387,200 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
66,387,200
Owned by Insiders
21.49%
Owned by Institutions
54.01%

Financial Efficiency

Bicara Therapeutics Inc.’s return on equity (ROE) is -0.34 and return on invested capital (ROIC) is -38.60%.

Return on Equity (ROE)
-0.34
Return on Assets (ROA)
-0.32
Return on Invested Capital (ROIC)
-38.60%
Return on Capital Employed (ROCE)
-0.39
Revenue Per Employee
0
Profits Per Employee
-1.34M
Employee Count
103
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Bicara Therapeutics Inc. is -2.73. Bicara Therapeutics Inc.’s PEG ratio is 0.07.

PE Ratio
-2.73
PS Ratio
0.00
PB Ratio
1.58
Price to FCF
-3.87
Price to Operating Cash Flow
-4.01
PEG Ratio
0.07

Income Statement

In the last 12 months, Bicara Therapeutics Inc. had revenue of 0 and earned -137.95M in profits. Earnings per share was -2.52.

Revenue
0
Gross Profit
0
Operating Income
-155.60M
Pretax Income
-137.73M
Net Income
-137.95M
EBITDA
-137.63M
Earnings Per Share (EPS)
-2.52

Cash Flow

In the last 12 months, operating cash flow was -161.73M and capital expenditures -1.02M, giving a free cash flow of -162.75M billion.

Operating Cash Flow
-161.73M
Free Cash Flow
-162.75M
Free Cash Flow per Share
-2.38

Dividends & Yields

Bicara Therapeutics Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-26.13%
Earnings Yield
-34.34%

Stock Price Statistics

Beta
1.71
52-Week Price Change
-36.21%
50-Day Moving Average
16.84
200-Day Moving Average
20.94
Relative Strength Index (RSI)
33.17
Average Volume (3m)
1.17M

Important Dates

Bicara Therapeutics Inc. upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 09, 2026
Next Earnings Date
Apr 01, 2027
Ex-Dividend Date
―

Financial Position

Bicara Therapeutics Inc. as a current ratio of 14.58, with Debt / Equity ratio of 0.43%

Current Ratio
14.58
Quick Ratio
14.58
Debt to Market Cap
0.00
Net Debt to EBITDA
0.69
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Bicara Therapeutics Inc. has paid 217.00K in taxes.

Income Tax
217.00K
Effective Tax Rate
-0.00

Enterprise Valuation

Bicara Therapeutics Inc. EV to EBITDA ratio is -2.46, with an EV/FCF ratio of -3.33.

EV to Sales
0.00
EV to EBITDA
-2.46
EV to Free Cash Flow
-3.33
EV to Operating Cash Flow
-3.35

Balance Sheet

Bicara Therapeutics Inc. has $442.35M in cash and marketable securities with $880.00K in debt, giving a net cash position of $441.47M billion.

Cash & Marketable Securities
$442.35M
Total Debt
$880.00K
Net Cash
$441.47M
Net Cash Per Share
$6.65
Tangible Book Value Per Share
$5.99

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for Bicara Therapeutics Inc. is $31.78, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
$31.78
Price Target Upside
231.02% Upside
Analyst Consensus
Strong Buy
Analyst Count
9
Revenue Growth Forecast
―
EPS Growth Forecast
-55.27%

Scores

Smart Score
4
AI Score
49